Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Qiagen and Seegene to expand QIAsymphony test menu

Qiagen and Seegene to expand QIAsymphony test menu

9th July 2015

Qiagen is to develop a menu of multiplex assay panels for its modular QIAsymphony RGQ MDx automation platform in collaboration with Seegen.

The first project under this new alliance will focus on developing comprehensive panels to profile infectious diseases, utilising Seegene's proprietary technologies for multiplexed real-time PCR analysis to enable simultaneous amplification of up to 20 target genes per tube in a single reaction.

Qiagen will be responsible for validating the new tests to run on its flagship automation solution and will market them worldwide, beginning in Europe and Asia.

The current range of diagnostics running on the QIAsymphony platform includes 13 CE-IVD marked tests available in 30 European countries.

Thierry Bernard, senior vice-president, head of the molecular diagnostics business area and a member of the executive committee of Qiagen, said: "QIAsymphony is adding significant value for users as the growing menu of clinically proven diagnostics allows labs to consolidate more tests on one system. The new tests will be highly synergistic with our current menu."

Last month, the firm announced a new partnership with Biotype Diagnostics to create a joint venture company called Biotype Innovation.ADNFCR-8000103-ID-801793885-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.